Santoni, N. et al. 2017. Cost-effectiveness of afatinib versus pemetrexed plus cisplatin, erlotinib and gefitinib as first line treatment in patients with locally advanced or metastatic epidermal growth factor receptor mutation (EFGR+) non-small cell lung cancer in the Brazil. Jornal Brasileiro de Economia da Saúde. 9, 1 (abr. 2017), 73–82. DOI:https://doi.org/10.21115/JBES.v9.n1.p73-82.